Long-term efficacy of risankizumab maintained in psoriatic arthritis
Click Here to Manage Email Alerts
MILAN — Long-term treatment with risankizumab maintained efficacy in psoriatic arthritis through 100 weeks, according to a study presented at the European Academy of Dermatology and Venereology Congress.
“As a clinician who treats patients with psoriatic arthritis, this suggests that risankizumab is indeed a competent treatment for psoriatic arthritis and that the effect might appreciate is maintained in the long term,” Kim A. Papp, MD, PhD, president and director of research at Probity Medical Research and one of the study’s investigators, told Healio.
Papp presented extension study data from the phase 3 KEEPsAKE 1 and KEEPsAKE 2 clinical trials. In the initial trials, patients were randomly assigned to receive 150 mg of risankizumab (Skyrizi, AbbVie) or placebo at weeks 0, 4 and 16. At week 24, all patients received open label risankizumab every 12 weeks.
“The purpose of KEEPsAKE 1 and KEEPsAKE 2 is really to evaluate the effectiveness of risankizumab in the treatment of psoriatic arthritis across the core domains, which is tender and swollen joints using [American College of Rheumatology (ACR)] scores or response levels as primary endpoints, but in addition, looking at other clinical features,” Papp said.
At week 100, of the patients who received the study drug for the duration of the KEEPsAKE 1 trial, 64.3% achieved ACR 20, 42.4% achieved ACR 50, 26.7% achieved ACR 70 and 71.3% achieved PASI 90. Additionally, of those who switched from placebo to the study drug, 62.1% achieved ACR 20 and 67.8% achieved PASI 90.
At week 100, of the patients randomly assigned to risankizumab for the duration of the KEEPsAKE 2 trial, 57.1% achieved ACR 20, 34.8% achieved ACR 50, 21.4% achieved ACR 70 and 67.5% achieved PASI 90. Also, of those who switched from placebo to the study drug, 52.5% achieved ACR 20 and 61.3% achieved PASI 90.
Minimal disease activity was reached by 38.2% and 33% of patients in the original risankizumab groups.
For patients who achieved ACR response at week 52, that response was mostly maintained through week 100.
“Clinicians and dermatologists already know risankizumab is very effective in the treatment of cutaneous psoriasis. Now we’ve expanded it across a larker segment of psoriatic disease,” Papp said. “In fact, encompassing the two far and away largest constituents of psoriatic diseases — skin and joints — risankizumab has demonstrated that it’s effective in treating both and not just in the short term.”